Background LS women have a 40-60 % lifetime risk of endometrial cancer (EC). Most international guidelines recommend screening. However, data on efficacy are limited. Purpose To assess the performance of OHES for EC screening in LS and compare it with transvaginal ultrasound (TVS) alone. Methods A prospective observational cohort study of LS women attending a tertiary high-risk familial gynaecological cancer clinic was conducted. LS women opting for EC screening underwent annual OHES and TVS. Histopathological specimens were processed using a strict protocol. Data of women screened between October 2007 and March 2010 were analysed from a bespoke database. Histology was used as the gold standard. Diagnostic accuracy of OHES was compared with TVS using specificity, and positive (PLR) and negative (NLR) likelihood ratios. Results Forty-one LS women underwent 69 screens (41 prevalent, 28 incident). Four (three prevalent, one incident) women were detected to have EC/atypical endometrial hyperplasia (AEH), five had endometrial polyps and two had endometrial hyperplasia (EH) on OHES. TVS detected two of four EC/AEH. OHES had similar specificity of 89.8 % (CI 79.2, 96.2 %), but higher PLR 9.8 (CI 4.6, 21) and lower NLR (zero) compared to TVS: specificity 84.75 %(CI 73, 92.8 %), PLR 3.28 (CI 1.04, 10.35) and NLR 0.59 (CI 0.22, 1.58). No interval cancers occurred over a median follow-up of 22 months. The annual incidence was 3.57 % (CI 0.09, 18.35) for EC, 10.71 % (CI 2.27, 28.23) for polyps and 21.4 % (CI 8.3, 40.1) for any endometrial pathology. Conclusions Our findings suggest that in LS, annual OHES is acceptable and has high diagnostic accuracy for EC/AEH screening. Larger international studies are needed for confirmation, given the relatively small numbers of LS women at individual centres. It reinforces the current recommendation that endometrial sampling is crucial when screening these women.
(MMR) genes: MLH1, MSH2, MSH6 and PMS2 [1] . Strict family history-based diagnostic criteria (Amsterdam criteria (AC)-II) [2] are used to identify people at increased risk. Lynch syndrome women have a 40-60 % lifetime risk for endometrial cancer (EC). Some data suggest that EC risk may be higher than that of colorectal cancer (CRC) [3, 4] and greater for MSH2 and MSH6 than for MLH1 carriers [3] [4] [5] [6] .
Gynaecological surveillance with endometrial sampling has been recommended for women of age 30-35 years who wish to delay/avoid risk-reducing surgery [5, 7] . Unlike screening for CRC, the efficacy of EC screening remains unproven with only a handful of published series evaluating different modalities for EC screening in LS. These include: (1) transvaginal (TVS) and/or transabdominal ultrasound [8] [9] [10] ; (2) TVS and endometrial sampling [9, 11] ; and (3) hysteroscopy [12, 13] .
The possibility of using hysteroscopy as a screening modality in LS was initially suggested in 2002 [14] . However, no screen-detected cancers have been reported in the published literature. In this paper, we report on our initial experience of annual outpatient hysteroscopy and endometrial sampling (OHES) as a screening strategy for EC in women with LS and compare it with TVS alone.
Methods
The familial gynaecological cancer clinic at University College London Hospital is a tertiary clinic for managing women at 'high risk' of gynaecological cancers. All women attending the clinic are managed by a multidisciplinary team, which includes gynaecological oncologist, clinical geneticist, clinical psychologist, radiologist, clinical nurse specialist, minimal access gynaecologist and pathologist. All women attending the clinic undergo detailed pedigree-based risk assessment and counselling. They receive comprehensive advice on advantages and disadvantages of risk-reducing surgery and screening, as well as reproductive and lifestyle issues.
High-risk women with LS are identified on the basis of the diagnostic AC-II criteria [2] or the presence of an MMR gene mutation. Lynch syndrome women [ 35-40 years, who have completed their family, are offered riskreducing surgery: total laparoscopic hysterectomy (TLH), bilateral salpingo-oophorectomy (BSO) and peritoneal washings. Women [ 35 years are offered screening for ovarian cancer within the UK Familial Ovarian Cancer Screening Study (UKFOCSS).
Since October 2007, eligible LS women attending the clinic are offered EC screening with TVS and OHES. Inclusion criteria are: LS women [ 30 years age. Exclusion criteria are: current pregnancy, prior hysterectomy, women opting for risk-reducing surgery or those negative on predictive testing for a known familial mutation. Women keep a menstrual calendar and undergo annual TVS with endometrial thickness (ET) measurement and OHES. TVS is performed by experienced ultrasonographers with over 10 years of scanning experience. Hysteroscopy is carried out by one of a team of three experienced hysteroscopists, in an office setting, as described previously [15] . Endometrial sampling is undertaken in all women using guided biopsies/polypectomy where indicated and/or a Pipelle device (Laboratoire CCD, France) at the end of the procedure [15] . Any irregular, heavy or unscheduled vaginal bleeding reported is investigated by bringing forward the annual OHES. Histological specimens are processed in total by a dedicated senior pathologist (EB). All data are stored on a bespoke database.
The current analysis includes all OHES procedures between October 2007 and March 2010. The primary outcome was EC and atypical endometrial hyperplasia (AEH). Inclusion of AEH as an outcome was based on it being an established premalignant lesion, lack of concordance in the diagnosis of AEH or EC between pathologists [16] and 42.6 % of AEH having concurrent EC [17] . Wherever necessary, case notes, histopathology and TVS/ biochemistry reports were reviewed. A screen positive on TVS is defined as (1) ET [ 5 mm (measuring both endometrial layers): postmenopausal women [18] , (2) ET [ 12 mm (measuring both endometrial layers in the second week of the cycle): premenopausal women [10] , (3) presence/suspicion of a polyp or (4) irregular endometrium with fluid in the cavity. Although a cutoff of 4 mm for endometrial thickness has been used by some to triage symptomatic postmenopausal women for hysteroscopy, we use a cutoff of 5 mm in our practice, which is consistent with that advocated by a number of other institutions, a meta-analysis [18] and systematic review [19] . In addition, our experience of modelling endometrial thickness in asymptomatic postmenopausal women indicates that the best performance characteristic may be obtained at a cutoff of 5.1 mm [20] . Cutoffs for endometrial thickness in asymptomatic premenopausal women unlike those for postmenopausal women are not well defined. The 12-mm cutoff was chosen on the basis of an earlier published report in the literature which evaluated TVS for screening in these women [10] . A screen positive at OHES is defined by the histology report.
Statistical analysis was undertaken using SPSS 12.0.1. The Mann-Whitney test was used to compare age distributions between groups after reviewing histograms. Fisher's test was used to calculate the difference between proportions. Kaplan-Meier curves and the log rank test were used to evaluate any difference in time to diagnosis. Two-sided p values are reported for all statistical tests. Confidence intervals for a single proportion were calculated using the statistics package 'Measuring Usability' (J Sauro) LLC, Denver, CO, USA. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), negative likelihood ratio (NLR) and positive likelihood ratio (PLR) were used to compare the screening performance for TVS and OHES.
Results
Between March 2004 and March 2010, 69 women with LS (fulfilling AC-II) [2] attended the clinic, of whom 25 were known mutation carriers (12MLH1, 12MSH2, 1PMS2). Thirteen women preferred risk-reducing surgery, five moved away, two were \30 years age and two tested negative for a familial mutation. The remaining 47 women opted for EC screening. Four eventually declined OHES and two have an appointment scheduled ( Fig. 1 ). The characteristics of the remaining cohort (41) are described in Table 1 .
Between October 2007 and March 2010, 41 prevalent and 28 incident screens (49.2 women screen years) were performed. The screening outcomes of the cohort are described in Fig. 1 . There was one failed outpatient hysteroscopy procedure which was completed under a general anaesthetic.
At prevalence screen, 39 were asymptomatic and 2 complained of irregular periods with intermenstrual bleeding. One of the symptomatic women (benign polyp) and 6 of the 39 (15.4 %) asymptomatic women had an abnormal TVS (2 endometrial polyps, 3 ET [ 12 mm, 1 irregular endometrium/fluid in the cavity), of whom 1 (polyp) had EC at histology. Three asymptomatic women were detected to have EC/AEH on OHES. Two of these three women with EC/AEH underwent hysterectomy because of prevalence screen-detected EC/AEH and six women opted for risk-reducing surgery after their initial prevalent screen. Transvaginal ultrasound and OHES in these six women were normal. Twenty-two eligible women underwent incident screen-1 ( Fig. 1 ). Of these, three (13.6 %) presented with abnormal bleeding at 9-11 months from last screen. One had an in situ levonorgestrel intrauterine system (LNG-IUS, Mirena Ò Schering Health Care). None had EC/AEH. All three had a normal TVS. Of the 19 (86.4 %) asymptomatic women, TVS was abnormal in 5 (26.3 %) which included the 1 woman with EC. This woman underwent hysterectomy following incident screen-detected EC. Of the 22 incident screen-1 women, 6 underwent a subsequent second incident screen (incident screen-2) during the study time period (Fig. 1 ). Of these, five were asymptomatic with normal TVS. However, endometrial hyperplasia (EH) was found at OHES in two of these cases.
Overall, three women (two prevalence, one incident screen) had EC and one woman had AEH (prevalence screen) ( Table 2 ). The latter includes one woman initially diagnosed with AEH who had a stage 1a, grade 1 EC at TLH BSO. Three of four women with screen-detected endometrial pathology were MMR mutation carriers. No adjuvant treatment was needed for any of the three EC cases who remain recurrence free at 10, 16 Table 3) .
The median age of women with EC/AEH was 40.9 years (IQR 5.3 years) and the median age for the rest of the screened cohort was 43 years (IQR 12.3 years). EC/AEH cases were not found to differ from the rest of the cohort with respect to mutation status (P = 0.64), number of screens (P = 0.70) or age (Mann-Whitney, P = 0.40). However, mutation carriers undergoing screening had a significantly younger median age (39.7 years, IQR 6.3) than the remaining AC-II positive women (44.2 years, IQR 12.8) (P = 0.022). Kaplan-Meier and log rank analysis of time to diagnosis for EC/AEH did not show any difference between known MMR carriers and those fulfilling AC-II alone (P = 0.85).
Additional pathology found in this cohort included six endometrial polyps (three prevalent and three incident). The annual incidence rate was 3.57 % (95 % CI 0.1, 18.35) for EC/AEH, 10.71 % (95 % CI 2.27, 28.23) for polyps and 7.1 % (95 % CI 0.88, 23.5) for EH (Table 4) .
Discussion
This is to our knowledge the first series reporting the diagnosis of early-stage EC in asymptomatic LS women using hysteroscopy-based screening. Our findings indicate that OHES has high specificity and PLR and low NLR. The higher annual incidence rate of EC in our cohort (3.57 %; 95 % CI 0.09, 18.35) compared to the expected rate of approximately 1 % in this population suggests that there may be lead time. OHES seems superior to TVS alone as a test for detecting EC/AEH in these women (Table 3) , with all four women with EC/AEH being detected by OHES compared to TVS which only detected two. The data further support the current guidelines that recommend that endometrial sampling should be undertaken in all LS women [7, 21] .
Transvaginal ultrasound alone had a PLR of 3.28 for EC/AEH and NLR of 0.59 for EC/AEH. In contrast, OHES achieved an overall PLR of 9.8 for EC/AEH and an NLR of zero. Likelihood ratio combines information about sensitivity and specificity to assess test performance. It is independent of prevalence and permits comparisons across different types of tests. A value close to one has little clinical significance as the posttest probability (odds) of The results suggest that TVS alone as a screening test has poor ability to detect or rule out disease and is not very helpful in clinical decision making, while OHES has good diagnostic ability to detect disease and excellent ability to rule out disease in LS, making it an effective test for endometrial screening. For comparison, the PLR and NLR for mammography are 9.4 and 0.19 [22] , and for CT pulmonary angiogram in diagnosing pulmonary embolism 8.6 and 0.06, respectively [23] . OHES performance in asymptomatic women in our series is consistent with the previously reported performance in symptomatic women (PLR 60.9, NLR 0.15) for diagnosing EC [24] , with a negative hysteroscopy reducing EC probability to 0.6 % [24] .
Transvaginal ultrasound alone would have missed two of four cases of EC/AEH, and did not seem to add to the performance of OHES. Our findings are consistent with a previous series using TVS and endometrial sampling, which found that 55 % (6/11) of the screen-detected EC, 50 % (2/4) AEH and 50 % of complex hyperplasia (four/ eight) cases had a normal TVS [11] . A majority of these false negative cases were postmenopausal. An increase in screen-detected EC/AEH cases has been reported when TVS-guided screening was replaced by a combined approach of TVS and endometrial sampling [9] . Overall, our findings and these data suggest that in contrast to symptomatic postmenopausal general population women, the performance of TVS for detecting endometrial pathology in asymptomatic (pre-and postmenopausal) LS women undergoing screening is poor. Reliable cutoffs for premenopausal and asymptomatic postmenopausal LS women are unknown. Two previous series have compared TVS alone to a combination of TVS and endometrial sampling and found the latter to be better at detecting EC/AEH [9, 11] .
There are limitations to the use of Pipelle endometrial sampling alone, including variability in its performance with menopausal status and type of pathology [25] . Reliable performance characteristics in asymptomatic LS women (significant proportion of whom are premenopausal) are not available. Cancers have been missed on Pipelle alone, with 3 of the 11 cases of EC not detected on endometrial sampling in a previous LS series [11] .
The median age of our cohort was 42.9 (95 % CI 39.4, 49.7) years. Known MMR carriers undergoing screening were significantly younger than those fulfilling AC-II alone. This may reflect increased screening awareness among gene carriers and increased uptake of preventative surgery by older mutation carriers. The median age (40.9 years, IQR 38.3, 43.5) of women diagnosed with EC/ AEH in our study is significantly lower than that reported in two previous series using TVS and endometrial sampling: (1) 51.5 years (IQR 47, 54, P = 0.016) [11] , median age of the entire cohort not reported and (2) 51 years (IQR 46, 55, P = 0.008 Mann-Whitney) with median age of cohort 46 years [9] . Our median age at diagnosis is also lower than that reported in epidemiological data (48-50 years) [3, 26] , though it lies within the expected range (27-72 years) found in LS [3, 26] . The small size of our data set makes it difficult to draw conclusions. If confirmed, age differences could be related to a combination of age and risk factor profile of our cohort and the lead time of screening.
The strengths of our study include a strict screening protocol with prospectively collected data, longitudinal follow-up and description of outcomes for both prevalence and incident screens. The main weakness is the small size of the cohort and the need for validation in larger multicentre studies. It is to be noted that previous reports on LS screening using hysteroscopy have involved up to 62 patients and no EC were detected. Although we have compared TVS and OHES, the standard practice in a number of institutions is screening using a combination of TVS and endometrial sampling. Transvaginal ultrasound alone has a poor detection rate for endometrial pathology. A limitation of our study is a lack of ability to directly compare OHES with TVS and endometrial sampling. Future research in this area should be directed towards addressing this issue. Given the small sample size in most centres, this will necessitate a multicentre international study.
We are not aware of any reports on incidence rate of endometrial pathology in LS women. We found that one in five (incidence rate 21.4 %; 95 % CI 8.3, 40.1) LS women had endometrial pathology with an annual incidence of polyps of 11 %. This included one woman with [27, 28] . Hysteroscopy detects lesions which may be missed by both TVS and Pipelle [15, 27, 28] and also permits directed biopsy from a focal lesion.
In the general population, up to 5 % of non-atypical EH and 30 % of AEH progress to EC [29] . It is unknown if the rates of progression are greater in the LS population with a much higher a priori risk for EC. We can speculate that subsequent EC may have been prevented or delayed in some of the cases of polyps/hyperplasia treated in our series. EC/AEH was found in 9.76 % (95 % CI 2.7, 23.1) cases, which is consistent with reports in the literature [10, 11] , though higher than rates reported in some series [8, 12, 13] .
Both hysteroscopy and Pipelle endometrial sampling are effective, easy to perform and well tolerated as outpatient procedures. Our failure rate of 1.45 % (95 % CI 0.04, 7.81) is consistent with those in systematic reviews (4.2 %, 95 % CI 3.9, 4.5) [24] . The compliance with annual screening suggests that this is acceptable. A recent study evaluating acceptability of screening found no significant difference in pain scores between either hysteroscopy or endometrial sampling [30] . The efficacy and patient acceptability of OHES is similar to the inpatient procedure and the former is more cost-effective [31, 32] . Preliminary data suggest that hysteroscopy-based endometrial screening in LS does not appear to be associated with any psychological morbidity [33] .
Conclusion
Lynch syndrome women have a high incidence of polyps, premalignant lesions and EC. Initial data suggest that an OHES-based surveillance strategy has good performance characteristics for detecting early-stage EC/AEH in LS and may be superior to that of TVS alone. However, definitive data would require a larger international study. The challenges are the relatively small numbers of LS women at individual centres, the rates of risk-reducing surgery and differences in use of routine outpatient hysteroscopy between countries.
